drugset / Trial / NCT06348303

Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg

NCT06348303

Non-randomizedCrossoverSingle-blindPrevention

Summary

Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks.

Timeline

Start
2024-05-16
Primary completion
2024-09-05
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metaxalone Small molecule 640 mg Oral
Comparator Metaxalone Small molecule 800 mg Oral

Indications

No indication recorded.